NeurologyLive® Staff

Articles by NeurologyLive® Staff

NDA Green Lighted For Diazepam Buccal Film, Solanezumab and Gantenerumab Fail in Alzheimer Trial, Mind Moments Episode 7 Live

ByNeurologyLive® Staff

February 15th 2020

Neurology News Network for the week ending February 15, 2020.

NeurologyLive Friday 5 — February 14, 2020

ByNeurologyLive® Staff

February 15th 2020

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending February 14, 2020.

NDA Submitted For CBD in Tuberous Sclerosis Complex, Ataluren Improves Walking Ability in DMD, Lasmiditan Available in Pharmacies

ByNeurologyLive® Staff

February 8th 2020

Neurology News Network for the week ending February 8, 2020.

NeurologyLive Friday 5 — February 7, 2020

ByNeurologyLive® Staff

February 8th 2020

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending February 7, 2020.

New ICD-10 Codes Added for Dravet Syndrome

ByNeurologyLive® Staff

February 5th 2020

The new codes listed by the World Health Organization include changes to Dravet syndrome, status epilepticus, and epilepsy in infants.

Dravet Syndrome Foundation Live Video Education Session

ByNeurologyLive® Staff

February 5th 2020

Dravet Syndrome Foundation is pleased to announce a new, live video education session on Thursday, February 13, 2020 at 2pm ET.

Investigational Dyskinesia Treatment Gets FDA Green Light

ByNeurologyLive® Staff

February 4th 2020

The FDA has approved the investigational new drug application for AV-101 for the treatment of dyskinesia in patients with Parkinson disease who are treated with levodopa.

2020 Dravet Syndrome Foundation Conference Registration Open

ByNeurologyLive® Staff

February 4th 2020

Dravet Syndrome Foundation has announced that registration for this year's DSF Conference is now open.

Phase 3b Trial of Aducanumab, Autoinjector FDA Approved for Fremanezumab, Ticagrelor Phase 3 Trial Announced

ByNeurologyLive® Staff

February 1st 2020

Neurology News Network for the week ending February 1, 2020.

NeurologyLive Friday 5 — January 31, 2020

ByNeurologyLive® Staff

February 1st 2020

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending January 31, 2020.

NDA Submission for Cataplexy Treatment, Siponimod Approved by EU for Progressive Multiple Sclerosis, RimabotulinumtoxinB Approved for Sialorrhea in Adults

ByNeurologyLive® Staff

January 25th 2020

Neurology News Network for the week ending January 27, 2020.

NeurologyLive Friday 5 — January 24, 2020

ByNeurologyLive® Staff

January 25th 2020

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending January 24, 2020.

FDA Approves Intranasal Diazepam, Rimegepant and Erenumab Effectively Treats Refractory Migraine, MS Treatments Double Since 2011

ByNeurologyLive® Staff

January 18th 2020

Neurology News Network for the week ending January 18, 2020.

NeurologyLive Friday 5 — January 17, 2020

ByNeurologyLive® Staff

January 18th 2020

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending January 17, 2020.

New Neuroimaging Guidelines for Migraine, Lemborexant Improves Sleep Onset, Patients with Parkinsons Have Compromised Swimming Ability

ByNeurologyLive® Staff

January 11th 2020

Neurology News Network for the week ending January 11, 2020.

Huntington Disease Trial Results; Mind Moments Podcast Now Live; PMM Trial Falls Short

ByNeurologyLive® Staff

January 4th 2020

Neurology News Network for the week ending January 4, 2020.

Amylyx Announces ALS Investigational Agent, FDA Approves Golodirsen for DMD, Wave Life Sciences Discontinues Suvodirsen, Discontinuation of Gosuranemab

ByNeurologyLive® Staff

December 21st 2019

Neurology News Network for the week ending December 21, 2019.

CBD Reduces Seizures in Tuberous Sclerosis Complex, Fenfluramine Reduces Seizure Frequency While Improving Executive Function, Intranasal Diazepam Effective to Treat Seizures Regardless of Usage Frequency

ByNeurologyLive® Staff

December 14th 2019

Neurology News Network for the week ending December 14, 2019.

FDA Grants Breakthrough Designation for RightEye Vision System, Results from ESETT Trial Released, Conference Coverage of the 73rd Annual Meeting of the American Epilepsy Society

ByNeurologyLive® Staff

December 7th 2019

Neurology News Network for the week ending December 7, 2019.

Dravet Syndrome Foundation Hosts Research Roundtable at AES 2019

ByNeurologyLive® Staff

December 4th 2019

The 10th annual DSF Research Roundtable will take place on Thursday, December 5, in Baltimore, Maryland.

FDA Granted Approval to Cenobamate, Risdiplam is Granted Priority Review Designation, Riluzole Oral Film FDA Approved for Treatment of ALS

ByNeurologyLive® Staff

November 30th 2019

Neurology News Network for the week ending November 30, 2019.

Ubrogepant Provides Pain Relief for Acute Migraine, Cenobamate Reduces Focal-onset Seizures, Valbenazine Decreases Involuntary Movements in Patients with Tardive Dyskinesia

ByNeurologyLive® Staff

November 23rd 2019

Neurology News Network for the week ending November 23, 2019.

Risdiplam Shows Positive Results in SMA, Study Trials for DMD Discontinued, Neflamapimod Granted Fast Track for Treatment of Dementia with Lewy Bodies

ByNeurologyLive® Staff

November 16th 2019

Neurology News Network for the week ending November 16, 2019.

Acute Ischemic Stroke Guidelines Updated, Stephen Hahn Nominated for FDA, Satralizumab Reduces Risk of Relapse in NMOSD

ByNeurologyLive® Staff

November 9th 2019

Neurology News Network for the week ending November 9, 2019.

Diroximel Fumarate Approved for MS; Personalized Interventions Improve Cognition; Zolgensma Trial Placed on Partial Hold

ByNeurologyLive® Staff

November 2nd 2019

Neurology News Network for the week ending October 28, 2019.

Aducanumab Reversal Sends Drug to FDA, Cala Trio Reduces Hand Tremor, Ganaxolone Promising in Refractory Status Epilepticus

ByNeurologyLive® Staff

October 26th 2019

Neurology News Network for the week ending October 26, 2019.

Lasmiditan Approved for Acute Migraine, Istradefylline Now Available for Parkinson Off Episodes, Omaveloxolone Promising in Friedreich's Ataxia

ByNeurologyLive® Staff

October 19th 2019

Neurology News Network for the week ending October 19, 2019.

Edasalonexent Promising for DMD, nVNS May Resolve Vestibular Migraine Symptoms, NIA Backs New Alzheimer Disease Research Centers

ByNeurologyLive® Staff

October 12th 2019

Neurology News Network for the week ending October 12, 2019.

RimabotulinumtoxinB for Sialorrhea, Zogenix Resubmits Fenfluramine NDA, Long-Term Lemborexant Insomnia Data

ByNeurologyLive® Staff

October 5th 2019

Neurology News Network for the week ending October 5, 2019.

Are Multiple Sclerosis Treatment Prices Interfering With Patient Care?

ByNeurologyLive® Staff

October 4th 2019

Unsustainable costs pose challenges for patients and providers alike as the price of living with MS continues to rise.

NeurologyLive® Staff

Articles by NeurologyLive® Staff

NDA Green Lighted For Diazepam Buccal Film, Solanezumab and Gantenerumab Fail in Alzheimer Trial, Mind Moments Episode 7 Live

NeurologyLive Friday 5 — February 14, 2020

NDA Submitted For CBD in Tuberous Sclerosis Complex, Ataluren Improves Walking Ability in DMD, Lasmiditan Available in Pharmacies

NeurologyLive Friday 5 — February 7, 2020

New ICD-10 Codes Added for Dravet Syndrome

Dravet Syndrome Foundation Live Video Education Session

Investigational Dyskinesia Treatment Gets FDA Green Light

2020 Dravet Syndrome Foundation Conference Registration Open

Phase 3b Trial of Aducanumab, Autoinjector FDA Approved for Fremanezumab, Ticagrelor Phase 3 Trial Announced

NeurologyLive Friday 5 — January 31, 2020

NDA Submission for Cataplexy Treatment, Siponimod Approved by EU for Progressive Multiple Sclerosis, RimabotulinumtoxinB Approved for Sialorrhea in Adults

NeurologyLive Friday 5 — January 24, 2020

FDA Approves Intranasal Diazepam, Rimegepant and Erenumab Effectively Treats Refractory Migraine, MS Treatments Double Since 2011

NeurologyLive Friday 5 — January 17, 2020

New Neuroimaging Guidelines for Migraine, Lemborexant Improves Sleep Onset, Patients with Parkinsons Have Compromised Swimming Ability

Huntington Disease Trial Results; Mind Moments Podcast Now Live; PMM Trial Falls Short

Amylyx Announces ALS Investigational Agent, FDA Approves Golodirsen for DMD, Wave Life Sciences Discontinues Suvodirsen, Discontinuation of Gosuranemab

CBD Reduces Seizures in Tuberous Sclerosis Complex, Fenfluramine Reduces Seizure Frequency While Improving Executive Function, Intranasal Diazepam Effective to Treat Seizures Regardless of Usage Frequency

FDA Grants Breakthrough Designation for RightEye Vision System, Results from ESETT Trial Released, Conference Coverage of the 73rd Annual Meeting of the American Epilepsy Society

Dravet Syndrome Foundation Hosts Research Roundtable at AES 2019

FDA Granted Approval to Cenobamate, Risdiplam is Granted Priority Review Designation, Riluzole Oral Film FDA Approved for Treatment of ALS

Ubrogepant Provides Pain Relief for Acute Migraine, Cenobamate Reduces Focal-onset Seizures, Valbenazine Decreases Involuntary Movements in Patients with Tardive Dyskinesia

Risdiplam Shows Positive Results in SMA, Study Trials for DMD Discontinued, Neflamapimod Granted Fast Track for Treatment of Dementia with Lewy Bodies

Acute Ischemic Stroke Guidelines Updated, Stephen Hahn Nominated for FDA, Satralizumab Reduces Risk of Relapse in NMOSD

Diroximel Fumarate Approved for MS; Personalized Interventions Improve Cognition; Zolgensma Trial Placed on Partial Hold

Aducanumab Reversal Sends Drug to FDA, Cala Trio Reduces Hand Tremor, Ganaxolone Promising in Refractory Status Epilepticus

Lasmiditan Approved for Acute Migraine, Istradefylline Now Available for Parkinson Off Episodes, Omaveloxolone Promising in Friedreich's Ataxia

Edasalonexent Promising for DMD, nVNS May Resolve Vestibular Migraine Symptoms, NIA Backs New Alzheimer Disease Research Centers

RimabotulinumtoxinB for Sialorrhea, Zogenix Resubmits Fenfluramine NDA, Long-Term Lemborexant Insomnia Data

Are Multiple Sclerosis Treatment Prices Interfering With Patient Care?

Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights

Investigational COYA 302 Shows Feasibility, Preliminary Efficacy in Small Trial of Frontotemporal Dementia

Efficacy and Safety Data for Tavapadon as an Emerging Therapy in Parkinson’s Disease

Phase 1b Trial for Solid Biosciences’ Friedreich Ataxia Gene Therapy SGT-212 Doses First Patient

Phase 3 VALOR Data Further Support Tofersen’s Impact on ALS Disease Progression, Survival

EP. 2 Assessing Depressive Symptoms in Children with Epilepsy and Lower IQ

NeurologyLive® Staff

Articles by NeurologyLive® Staff

NDA Green Lighted For Diazepam Buccal Film, Solanezumab and Gantenerumab Fail in Alzheimer Trial, Mind Moments Episode 7 Live

NeurologyLive Friday 5 &mdash; February 14, 2020

NDA Submitted For CBD in Tuberous Sclerosis Complex, Ataluren Improves Walking Ability in DMD, Lasmiditan Available in Pharmacies

NeurologyLive Friday 5 &mdash; February 7, 2020

New ICD-10 Codes Added for Dravet Syndrome

Dravet Syndrome Foundation Live Video Education Session

Investigational Dyskinesia Treatment Gets FDA Green Light

2020 Dravet Syndrome Foundation Conference Registration Open

Phase 3b Trial of Aducanumab, Autoinjector FDA Approved for Fremanezumab, Ticagrelor Phase 3 Trial Announced

NeurologyLive Friday 5 &mdash; January 31, 2020

NDA Submission for Cataplexy Treatment, Siponimod Approved by EU for Progressive Multiple Sclerosis, RimabotulinumtoxinB Approved for Sialorrhea in Adults

NeurologyLive Friday 5 &mdash; January 24, 2020

FDA Approves Intranasal Diazepam, Rimegepant and Erenumab Effectively Treats Refractory Migraine, MS Treatments Double Since 2011

NeurologyLive Friday 5 &mdash; January 17, 2020

New Neuroimaging Guidelines for Migraine, Lemborexant Improves Sleep Onset, Patients with Parkinsons Have Compromised Swimming Ability

Huntington Disease Trial Results; Mind Moments Podcast Now Live; PMM Trial Falls Short

Amylyx Announces ALS Investigational Agent, FDA Approves Golodirsen for DMD, Wave Life Sciences Discontinues Suvodirsen, Discontinuation of Gosuranemab

CBD Reduces Seizures in Tuberous Sclerosis Complex, Fenfluramine Reduces Seizure Frequency While Improving Executive Function, Intranasal Diazepam Effective to Treat Seizures Regardless of Usage Frequency

FDA Grants Breakthrough Designation for RightEye Vision System, Results from ESETT Trial Released, Conference Coverage of the 73rd Annual Meeting of the American Epilepsy Society

Dravet Syndrome Foundation Hosts Research Roundtable at AES 2019

FDA Granted Approval to Cenobamate, Risdiplam is Granted Priority Review Designation, Riluzole Oral Film FDA Approved for Treatment of ALS

Ubrogepant Provides Pain Relief for Acute Migraine, Cenobamate Reduces Focal-onset Seizures, Valbenazine Decreases Involuntary Movements in Patients with Tardive Dyskinesia

Risdiplam Shows Positive Results in SMA, Study Trials for DMD Discontinued, Neflamapimod Granted Fast Track for Treatment of Dementia with Lewy Bodies

Acute Ischemic Stroke Guidelines Updated, Stephen Hahn Nominated for FDA, Satralizumab Reduces Risk of Relapse in NMOSD

Diroximel Fumarate Approved for MS; Personalized Interventions Improve Cognition; Zolgensma Trial Placed on Partial Hold

Aducanumab Reversal Sends Drug to FDA, Cala Trio Reduces Hand Tremor, Ganaxolone Promising in Refractory Status Epilepticus

Lasmiditan Approved for Acute Migraine, Istradefylline Now Available for Parkinson Off Episodes, Omaveloxolone Promising in Friedreich's Ataxia

Edasalonexent Promising for DMD, nVNS May Resolve Vestibular Migraine Symptoms, NIA Backs New Alzheimer Disease Research Centers

RimabotulinumtoxinB for Sialorrhea, Zogenix Resubmits Fenfluramine NDA, Long-Term Lemborexant Insomnia Data

Are Multiple Sclerosis Treatment Prices Interfering With Patient Care?

Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights

Investigational COYA 302 Shows Feasibility, Preliminary Efficacy in Small Trial of Frontotemporal Dementia

Efficacy and Safety Data for Tavapadon as an Emerging Therapy in Parkinson’s Disease

Phase 1b Trial for Solid Biosciences’ Friedreich Ataxia Gene Therapy SGT-212 Doses First Patient

Phase 3 VALOR Data Further Support Tofersen’s Impact on ALS Disease Progression, Survival

EP. 2 Assessing Depressive Symptoms in Children with Epilepsy and Lower IQ

NeurologyLive Friday 5 — February 14, 2020

NeurologyLive Friday 5 — February 7, 2020

NeurologyLive Friday 5 — January 31, 2020

NeurologyLive Friday 5 — January 24, 2020

NeurologyLive Friday 5 — January 17, 2020